Project Serotonin has announced the launch of its first specialised protocol, the Gut Health Protocol, developed on its eighth-generation scalable AI/ML-enabled precision health platform. Smiles Institute of Gastroenterology will deploy the protocol across its patient care pathways under the clinical stewardship of Dr CM Parameshwara.
The Gut Health Protocol is the first in a planned series of specialised protocols that will extend Project Serotonin’s platform into specific health domains to function as therapy adjuncts. These protocols are built using genetics-first and whole system approaches, considering variables including genetics, blood and urine biomarkers, diet, age, gender and lifestyle that may affect health outcomes. The protocols follow real-world pilots for efficacy and usability before release and are optimised for each user journey, with outcomes that are measurable and trackable over time.
Project Serotonin’s Gut Health Protocol identifies an individual’s inherited predispositions to digestive conditions and validates them through biomarker data. This integrated view enables personalised interventions, including dietary recommendations and supplements aimed at addressing biological drivers rather than symptoms. Recommendations are refined as new data is collected, functioning as a therapy adjunct alongside clinical care.
Explaining the approach, Dr Ashwat Visvanathan, Head – Partnerships and User Outcomes, Project Serotonin, said, “Our proprietary genetic models decode how your body is fundamentally wired, enabling us to correct gut-related issues through highly precise, personalized interventions across diet, supplements, and lifestyle. Smiles Institute of Gastroenterology’s decision to deploy the platform across its patient care pathways reflects a growing recognition among leading clinical institutions that precision foundational health when integrated into the treatment journey can meaningfully improve patient experience and long-term outcomes.”
Speaking on the association, Dr CM Parameshwara, CEO & Founder, Smiles Institute of Gastroenterology, said, “What drew us to Project Serotonin’s platform is the rigour of their approach starting from genetic predisposition, validating through biomarkers, and building corrective strategies that complement the clinical interventions we provide. Deploying this within our patient care pathways allows us, for the first time, to offer a precision, data-driven layer of foundational health optimisation that works alongside treatment and meaningfully improves the patient journey. By deploying Project Serotonin’s platform, we have gained access to a first-of-its-kind precision health infrastructure that has been built and refined over a decade.”
Despite the prevalence of genetic predispositions for gut-related conditions globally, most approaches to gut health remain focused on treating symptoms after they appear rather than addressing biological root causes. Imbalances in gut health have been associated with effects on mental health, thyroid health, skin and hair health, and immune health. There is also overlap of symptoms across different gut health conditions, making diagnosis complex.